GSK pulls off clean sweep of endpoint hits in anemia phase 3, positioning it to leapfrog AstraZeneca Blade runs toward Nasdaq in $353M SPAC deal for 2 2022 trials, money from BMS, Pfizer Fierce Biotech’s Rotten Tomatoes 2021 Sponsored: A New Reference Model for Clinical Trial Recruitment, Enrollment and Retention Success Blackstone bets on Autolus' CD19 CAR-T in $250M deal, clearing path to pivotal readout in 2022 Provention Bio, hit by AdComm rejection for lead drug, hires early research exec from Gossamer Gyroscope spins the wheel again as it taps Sanofi for $60M months after ditching IPO attempt ATP fuels Marengo with $80M for battle against cancers with former Merck KGaA oncology head in driver's seat Once-failed cancer drug from BioXcel ramps up immunotherapy in mouse models of pancreatic cancer iRhythm picks up the tempo with 19% revenue boost despite Medicare pricing letdown Many expectant mothers unlikely to get vaccinated for COVID-19, survey finds With oncology spinoff done, bluebird bio moves to new digs better suited to its future Featured Story | By Nick Paul Taylor GlaxoSmithKline has boosted its challenge for the anemia due to chronic kidney disease market, revealing a clean sweep of hits on key endpoints across two phase 3 clinical trials. But with the FDA rejecting AstraZeneca’s rival drug, doubts remain about GSK’s chances of getting to market. read more |
| |
|---|
|
Top Stories By Kyle LaHucik Pfizer Ventures and Bristol Myers Squibb contributed financing for Blade Therapeutics' special purpose acquisition company merger as the biotech gears up for two clinical trial starts in 2022. The $254 million in cash will bankroll trials in fibrosis and neurodegenerative conditions. read more By Ben Adams The biopharma industry has received acclaim during the COVID-19 pandemic. But while some companies have been working hard on life-saving therapies, others' actions have further stained the industry's already shaky reputation. read more Sponsored by: IPM.ai Rare diseases demand a modern recruitment approach grounded in uncovering the ideal, medically-eligible patient population with the highest propensity for study enrollment and retention. read more By Nick Paul Taylor Autolus Therapeutics has found a deep-pocketed supporter of its CD19 CAR-T therapy. Having seen Autolus’ stock halved over the past year, Blackstone Life Sciences has stepped in with a $250 million package to support the British biotech through to a pivotal readout and beyond. read more By Ben Adams Provention Bio has come out with a little bit of good news amid a tough 2021 as it hires former Gossamer Bio early R&D lead Miguel Sanjuan, Ph.D., to help shore up its early shots on goal. read more By Ben Adams The biotech IPO window, at the start of the year at least, was wide open, leaving more than a few people scratching their heads when the eye disease biotech said back in May it was ditching its plans because of “market conditions.” read more By Kyle LaHucik With $80 million to fuel its battle against cancer, Marengo Therapeutics will bring its first candidate into the clinic in late 2022. Former Merck KGaA global oncology leader Zhen Su will lead the way for the biotech, named after the French battle and Napoleon Bonaparte's horse. read more By Arlene Weintraub Georgetown researchers reported that combining BioXcel's DPP inhibitor talabostat with a PD-1 blocker in mouse models of pancreatic cancer slowed tumor growth and increased the recruitment of cancer-fighting immune cells. They're working to advance the combo into clinical trials. read more By Andrea Park For the third quarter in a row, iRhythm Technologies continued its streak of increasing revenues amid a host of challenges ranging from staffing shortages to lower-than-expected Medicare reimbursement rates to the ongoing COVID-19 pandemic. read more By Anastassia Gliadkovskaya Ovia Health, a family benefits solution, conducts monthly surveys of 4,500 users across each of its various apps on their attitudes toward the COVID-19 vaccine. Most remain hesitant, though most have discussed the benefits with their provider. read more By Eric Sagonowsky With many of its employees working from home and others having left for a new spinoff venture, Massachusetts-based bluebird bio has decided to move its headquarters from Cambridge three miles north to Somerville. The shift will save bluebird $120 million in overhead during the next six years, the company said. read more Resources Sponsored by: Catalent Biologics Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Blue Matter Consulting Paper describing how the chronic insomnia market offers big lessons for any biopharma company thinking about getting into digital therapeutics in any therapeutic area. Sponsored by: Medable, Inc. Find out how to improve clinical protocol adherence, and thus patient outcomes, by 15%+ with Medable’s latest White Paper. Sponsored by: TransPerfect Life Sciences Every detail is important when selecting a new eCOA solution; learn more about the current eCOA landscape, best practices, and crucial considerations for successful eCOA solution deployment in this white paper. Sponsored by: Informa Pharma Intelligence and Oracle Health Sciences New market research provides valuable insight into the impact of adaptations made in clinical trials during the pandemic. Sponsored by: Thermo Fisher Scientific Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific Sponsored by: Drexel University Online Drexel University’s online graduate programs in biomedicine, clinical research, drug discovery, and molecular medicine were developed with working professionals in mind, providing you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more. Sponsored by: Box Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization. Pharma Meeting Pros Summit November 3-4, 2021 | Atlantic City, NJ & Virtual Fierce Diversity, Equity & Inclusion Summit November 9–10, 2021 | Virtual Event Drug Development Boot Camp® 2021 VIRTUAL November 17-18, 2021 Learn impact of pricing, competitive assessment, epidemiology November 17-18, 2021 | Live & Online Fierce New Product Planning Summit December 1-2, 2021 | Boston, MA Fierce Launch Readiness for Medical Affairs & Communications Teams December 1-2, 2021 | Boston, MA Learn how therapeutics are successfully launched and commercialized December 1-2, 2021 | Live & Online 2nd Annual Symposium on Translational Medicine and Biomanufacturing December 2—3, 2021 Fierce Virtual Clinical Trials Summit December 6-7, 2021 | Philadelphia, PA Fierce JPM Week 2022 January 11, 2022 | San Francisco, CA
January 18-20, 2022 | Virtual Event Virtual European Healthcare Compliance Certificate Program January 24-28, 2022 2022 | Virtual Event February 8-9, 2022 | Location TBD April 2022 | Location TBD | 